Rituximab-Induced Interstitial Lung Disease: A Possible Underestimated Complication—A Systematic Review
Alexandra-Simona Zamfir, Mihai-Vasile Marinca, Carmen Lăcrămioara Zamfir, Gabriela Bordeianu, Andrada-Larisa Deac, Bogdan-Mihnea Ciuntu, Cătălina Teodora Pintilie, Doina Ojog, Marcela Brînză, Tudor Andrei Cernomaz · 2025
Read Rituximab-Induced Interstitial Lung Disease: A Possible Underestimated Complication—A Systematic Review by Alexandra-Simona Zamfir, Mihai-Vasile Marinca, Carmen Lăcrămioara Zamfir, Gabriela Bordeianu, Andrada-Larisa Deac, Bogdan-Mihnea Ciuntu, Cătălina Teodora Pintilie, Doina Ojog, Marcela Brînză, Tudor Andrei Cernomaz (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12691211.txt.
Description
A peer-reviewed research article from Europe PMC (2025). Simple SummaryRituximab is an effective therapy option for hematological malignancies and autoimmune diseases; interstitial lung disease is reported among its rarer side effects. Diagnosing this entity may be challenging as clinical and imaging findings are often nonspecific. We conducted a systematic review on rituximab-induced interstitial lung disease published data to provide an overview of its occurrence, clinical presentation, diagnostic features, treatment and outcomes.
Catalog record
| CREATOR | Alexandra-Simona Zamfir, Mihai-Vasile Marinca, Carmen Lăcrămioara Zamfir, Gabriela Bordeianu, Andrada-Larisa Deac, Bogdan-Mihnea Ciuntu, Cătălina Teodora Pintilie, Doina Ojog, Marcela Brînză, Tudor Andrei Cernomaz |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |